Abstract

Chimeric antigen receptor (CAR)-T cells have demonstrated significant clinical potential; however, their strong antitumor activity may cause severe adverse effects. To ensure efficacy and safe CAR-T cell therapy, it is important to understand CAR’s structure–activity relationship. To clarify the role of hinge and transmembrane domains in CAR and CAR-T cell function, we generated different chimeras and analyzed their expression levels and antigen-specific activity on CAR-T cells. First, we created a basic CAR with hinge, transmembrane, and signal transduction domains derived from CD3ζ, then we generated six CAR variants whose hinge or hinge/transmembrane domains originated from CD4, CD8α, and CD28. CAR expression level and stability on the T cell were greatly affected by transmembrane rather than hinge domain. Antigen-specific functions of most CAR-T cells depended on their CAR expression levels. However, CARs with a CD8α- or CD28-derived hinge domain showed significant differences in CAR-T cell function, despite their equal expression levels. These results suggest that CAR signaling intensity into T cells was affected not only by CAR expression level, but also by the hinge domain. Our discoveries indicate that the hinge domain regulates the CAR signaling threshold and the transmembrane domain regulates the amount of CAR signaling via control of CAR expression level.

Highlights

  • Adoptive T-cell transfer has been heralded as an ideal cancer treatment strategy that causes effective regression of primary cancer, suppresses metastasis and recurrence, and has few side effects on normal tissues [1,2]

  • Since chimeric antigen receptor (CAR) hinge domain (HD)/transmembrane domain (TMD) are assumed to regulate CAR expression level, we hypothesized that differences in hinge/transmembrane domains (HD/TMD) would affect the amount of CAR signal input to T cells

  • We aimed to reveal the role of HD/TMD in CAR activity and CAR-T cell function using a first-generation

Read more

Summary

Introduction

Adoptive T-cell transfer has been heralded as an ideal cancer treatment strategy that causes effective regression of primary cancer, suppresses metastasis and recurrence, and has few side effects on normal tissues [1,2]. The creation of T cells that genetically express a chimeric antigen receptor (CAR) and their use in next-generation adoptive T-cell transfer have been proposed to overcome current treatment limitations [3,4,5]. T cell genetic modification enables the rapid preparation of tumor-specific T cells with long-term antitumor effects [6,7,8,9]. The administered CAR-T cells exert cytotoxic activity by recognizing the target antigen on tumor cells via CAR, and proliferate and survive for a long time in vivo; even a single dose can continue to elicit sustained antitumor effects [8,9].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call